Abstract:It is well accepted that the balance of immunity between effector and regulatory T cells determines the outcome of autoimmune and chronic inflammatory diseases. Concerning the topic of ‘Regulatory and Effector T Cells’ as published in this issue of Journal of Molecular Cell Biology, several investigators have provided important new information. T-helper 1 (Th1) and Th2 cells represent the classical type of Th or effector cells. However, recent studies have also identified several new cell subsets of Th cells, including IL-9-producing T (Th9), IL-17-producing T (Th17), IL-22-producing T (Th22), and T follicular helper (Tfh) cells, extending the Th cell structure. Given their crucial role in the pathogenesis of autoimmune and inflammatory diseases, Th17 cells have received much attention. They mainly express IL-17A, but co-express IL-17B, IL-17E (IL-25), IL-17F, and IL-22. IL-26 is produced by human but not mouse Th17 cells. IL-17A is significantly more potent in initiating signaling and causing autoimmune responses than other cytokines produced by these cells. The differentiation of mouse Th17 cells needs the combination of IL-6 and transforming growth factor-beta (TGF-b) (Bettelli et al., 2006), although IL-6or TGF-b-independent pathways may also contribute to Th17 cell differentiation. The role of TGF-b in human Th17 cell differentiation is still controversial. Of note, the IL-21 and IL-1 signal pathways seem to be important in initiating Th17 cell development. IL-21 and IL-23 are also known to sustain and expand Th17 cells. Dr Ryffel’s group provides an updated account of the differentiation and function of Th17 cells, particularly during lung injury and inflammatory disease. They demonstrated that lung injury or allergen exposure leads to NLPR3 activation, with formation of the NLPR3 inflammasome complex and caspase-1 activation resulting in mature IL-1b, which may elicit IL-17 production. Traditionally, asthma is elicited by Th2 cells. It is still unclear whether Th17 cells work independent or together with Th2 cells in the development of asthma. They suggest that Th17 cells promote asthma through modulation of Th2 cells. In fact, IL-17E or IL-25, another IL-17 member, can induce Th2 cytokines and promote allergy. It is also possible that IL-17 regulates allergic responses independent of Th2 cells but Th2 cells promote asthma through Th17 cells since IL-4 does regulate IL-17 levels. It has been widely accepted that Tregs are critically involved in immune tolerance and homeostasis. Although this concept was suggested in early 1970s, it was resuscitated in 1990s when thymus-derived CD4+CD25+ cells were identified as natural Tregs (nTregs) (Sakaguchi et al., 1995). While Foxp3 has been identified as a unique marker and functional transcription factor for these cells, studies on Tregs have been greatly accelerated. As Treg frequency and functional alterations are associated with many autoimmune diseases, the manipulation of these cells provides a promising treatment possibility for autoimmune diseases. In addition, use of Tregs may be valuable in the prevention of graft rejection of organ transplantation and graft-versus-host disease (GVHD). Dr Bluestone’s group further provides information on the potential use of these cells in the clinic. They reported that by 2011, three clinical trials have been undertaken to test the safety of Treg therapy in GVHD, and all have demonstrated promising safety and efficacy profiles. Compelling evidence from animal models and human patients demonstrates that tolerance to allogeneic transplant can be achieved by reconditioning the immune system, so that troublesome global immunosuppression can be minimized or completely stopped. They emphasize that a sound trial design should harness the tolerogenic potential of Tregs while minimizing risks. One potential risk with Treg therapy is that these cells can purportedly exhibit some measure of plasticity. Since little is known about the appropriate doses of Tregs in humans, initial trials should be safety-centered evaluating effect of increasing

Clinical Remission of Sight-Threatening Non-Infectious Uveitis Is Characterized by an Upregulation of Peripheral T-Regulatory Cell Polarized Towards T-bet and TIGIT

[The Function and Changes of Immune Cells in Autoimmune Uveitis].

THU0229 Absolute Reduction of Peripheral Cd4+cd25+foxp3+t Regulatory Cells in Patients with Spondyloarthropathy-Related Oculopathy

Retina-Specific T Regulatory Cells Bring about Resolution and Maintain Remission of Autoimmune Uveitis

Recovery of CD226-TIGIT+FoxP3+ and CD226-TIGIT-FoxP3+ Regulatory T Cells Contributes to Clinical Remission from Active Stage in Ulcerative Colitis Patients

THU0412 Absolute reduction of peripheral cd4 + regulatory t cell subset of patients with systemic sclerosis and its restoration by short-term and low dose il-2 treatment

Unravelling T‐cell dynamics and immune responses in initial and recurrent uveitis

SAT0213 Low Dose Il-2 Restores Decreased Absolute Number of Regulatory T Cells and Imbalance Between Th17 and Regulatory T Cells in Patients with Rheumatoid Arthritis

Dysregulated Th17/Treg cell axis is correlated with local and systemic immune response in human intermediate uveitis.

AB0612 Efficacy of Low Dose and Short-Term IL-2 Treatment to Expand Endogenous Regulatory T Cells in Patients with Mixed Connective Tissue Disease

IL-10: A Key Regulator and potential therapeutic target in uveitis

Treatment With FoxP3+ Antigen-Experienced T Regulatory Cells Arrests Progressive Retinal Damage in a Spontaneous Model of Uveitis

Emerging Topics and New Perspectives on Regulatory and Effector T Cells.

Induction of Antigen-Specific Treg Cells in Treating Autoimmune Uveitis Via Bystander Suppressive Pathways Without Compromising Anti-Tumor Immunity

Increased Dysfunctional and Plastic Regulatory T Cells in Idiopathic Orbital Inflammation

Low-dose IL-2 improved clinical symptoms by restoring reduced regulatory T cells in patients with refractory rheumatoid arthritis: A randomized controlled trial

Breakdown of immune privilege and spontaneous autoimmunity in mice expressing a transgenic T cell receptor specific for a retinal autoantigen

An Observational Study in the Real Clinical Practice of the Treatment of Noninfectious Uveitis

Non-redundant Requirement for CXCR3 Signaling for Effective Treatment of CNS Autoimmunity with Type I Interferon

IL-6 blockade in the management of non-infectious uveitis

DOP32 CD226+TIGITneg expression identifies pathogenic inflammatory CD4+ memory T cells in severe Crohn’s Disease patients, opening up opportunities for patient-tailored treatment strategies